Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity [Seeking Alpha]
Biohaven Pharmaceutical Holding Company Ltd. Common Shares (BHVN)
Last biohaven pharmaceutical holding company ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Seeking Alpha
PFE's long-acting GLP-1 obesity program, bolstered by the Metsera acquisition, shows promise but lacks approval until at least 2028. Excluding Covid-19 products, PFE achieved 6% operational revenue growth in 2025, but total revenues declined 2% year-over-year. Meaningful upside hinges on competitive differentiation in obesity, successful integration of Seagen and Biohaven, and overcoming 2026 stagnation. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » mdisk/iStock via Getty Images The last time I spoke about Pfizer PFE ) it was with respect to a Seeking Alpha article entitled " Pfizer: Downgrade To 'Hold' On Lower 2026 Revenue Guidance And Potential Growth Tracks More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Pharmaceutical Holding Company Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven (NYSE:BHVN) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.MarketBeat
- Biohaven (NYSE:BHVN) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.MarketBeat
- Biohaven CEO Dr. Vlad Coric goes one-on-one with Jim Cramer [CNBC]CNBC
- Biohaven CEO Dr. Vlad Corcic goes one-on-one with Jim Cramer [CNBC]CNBC
- Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
BHVN
Earnings
- 11/10/25 - Beat
BHVN
Sec Filings
- 2/6/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- 1/7/26 - Form 4
- BHVN's page on the SEC website